Forcing courts to choose a single winner in the battle over competing class actions would exacerbate the problems of overlapping cases and encourage the race to court, class action powerhouse Maurice Blackburn said Wednesday.Â
The Australian maker of Difflam has taken UK consumer goods giant Reckitt Benckiser to court over ads for Strepfen that claim the rival lozenges provide ‘longer lasting relief’ from sore throats.
Law firm Squire Patton Boggs is again on the losing end of a ruling by the judge presiding over a shareholder class action against GetSwift, a case now better known for infighting among lawyers than for the allegations levelled against the tech startup.
Macquarie Bank is facing a fourth lawsuit by a group of former financial advisers alleging it breached the Fair Work Act by denying them regular wages.
US tyre company Goodyear wants to challenge a ruling in a long-running dispute with UK-based rival Dunlop over coveted trade marks for ‘Dunlop’ and ‘Flying D’.
A judge on Friday will hear arguments in a bid by BHP Billiton to halt a class action over the mining giant’s Brazilian mine disaster, a sweeping case filed on behalf of investors who held the company’s shares in Australia, the UK or South Africa.
The litigation funder underwriting a class action against Myer will have to fork over another $950,000 in security ahead of what will be a rare shareholder trial starting next Wednesday, a court has ruled.
One of Australia’s largest debt collectors, ACM Group, harassed and coerced vulnerable customers — including a stroke victim — by bombarding them with phone calls and making empty threats of litigation, the Federal Court found Monday.
The naming of Squire Patton Boggs as a concurrent wrongdoer in GetSwiftâs defence puts the law firm in an âimpossible position of conflict of interestâ if it wins a challenge to an order staying its class action against the company, the Full Federal Court has been told ahead of a highly anticipated appeal hearing that promises to pull no punches.
Two generic drug makers have lost their bid for confidential documents related to Neurim Pharmaceuticals’ patents covering sleep drug Circadin, with a court ruling legal professional privilege was waived in a phone conversation between a DLA Piper lawyer and the company’s founder.